Alan Heldman: Difference between revisions
m Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +) |
m Robot: Automated text replacement (-{{WikiDoc Cardiology Network Infobox}} +, -<references /> +{{reflist|2}}, -{{reflist}} +{{reflist|2}}) |
||
Line 1: | Line 1: | ||
{{SI}} | {{SI}} | ||
Latest revision as of 14:13, 4 September 2012
WikiDoc Resources for Alan Heldman |
Articles |
---|
Most recent articles on Alan Heldman Most cited articles on Alan Heldman |
Media |
Powerpoint slides on Alan Heldman |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Alan Heldman at Clinical Trials.gov Clinical Trials on Alan Heldman at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Alan Heldman
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Alan Heldman Discussion groups on Alan Heldman Patient Handouts on Alan Heldman Directions to Hospitals Treating Alan Heldman Risk calculators and risk factors for Alan Heldman
|
Healthcare Provider Resources |
Causes & Risk Factors for Alan Heldman |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Alan W. Heldman, M.D. (1962-) is an American interventional cardiologist.
Heldman graduated from Harvard College, University of Alabama School of Medicine, and completed residency and fellowship training at Johns Hopkins University School of Medicine. He held positions on the faculty of Johns Hopkins from 1995 to 2007. In 2007 he became Clinical Chief of Cardiology at the University of Miami, Leonard M. Miller School of Medicine.
He published one of the first studies showing that a drug-coated stent (now known as a drug-eluting stent) could prevent restenosis1. His research interests include delivery of stem cells to the heart for repair of myocardial infarction2.
His clinical interests include high risk and complex coronary intervention, and treatment of hypertrophic cardiomyopathy, including with alcohol septal ablation3.
References
1) Heldman A, Cheng L, Jenkins G, Heller P, Kim D, Ware M, Nater C, Hruban R, Rezai B, Abella B, Bunge K, Kinsella J, Sollott S, Lakatta E, Brinker J, Hunter W, Froehlich J (2001). "Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis.". Circulation 2001 May 8;103(18):2289-95. PMID 11342479
2) Amado LC, Saliaris AP, Schuleri KH, St John M, Xie JS, Cattaneo S, Durand DJ, Fitton T, Kuang JQ, Stewart G, Lehrke S, Baumgartner WW, Martin BJ, Heldman AW, Hare JM. Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Proc Natl Acad Sci U S A. 2005 Aug 9;102(32):11474-9. PMID: 16061805
3) Heldman AW, Wu KC, Abraham TP, Cameron DE. Myectomy or alcohol septal ablation: surgery and percutaneous intervention go another round. J Am Coll Cardiol. 2007 Jan 23;49(3):358-60. PMID: 17239718
Sources
http://www.hopkinshospital.org/Faculty/Heart/Heldman.html
http://www.hopkinsmedicine.org/mediaII/MNU/2006/infarction.html
http://www.hopkinsmedicine.org/mediaII/enews/newbeat.html
http://www.hopkinsmedicine.org/hmn/F02/feature1.html
http://www.hopkinsheart.org/media/cardiovascular-reports/Spring%202005%20CV%20Report.pdf